Cargando…
Design and rationale for a comparison study of Olmesartan and Valsartan On myocardial metabolism In patients with Dilated cardiomyopathy (OVOID) trial: study protocol for a randomized controlled trial
BACKGROUND: Dilated cardiomyopathy (DCMP) is characterized by ventricular chamber enlargement and systolic dysfunction which may cause heart failure. Patients with DCMP have overactivation of the renin-angiotensin-aldosterone systems, which can also adversely affect myocardial metabolism in heart fa...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760768/ https://www.ncbi.nlm.nih.gov/pubmed/35033178 http://dx.doi.org/10.1186/s13063-021-05970-7 |
_version_ | 1784633392073015296 |
---|---|
author | Jo, Sua Moon, Hyeyeon Park, Kyungil Sohn, Chang-Bae Kim, Jeonghwan Kwon, Yong-Seop Kim, Su Hong |
author_facet | Jo, Sua Moon, Hyeyeon Park, Kyungil Sohn, Chang-Bae Kim, Jeonghwan Kwon, Yong-Seop Kim, Su Hong |
author_sort | Jo, Sua |
collection | PubMed |
description | BACKGROUND: Dilated cardiomyopathy (DCMP) is characterized by ventricular chamber enlargement and systolic dysfunction which may cause heart failure. Patients with DCMP have overactivation of the renin-angiotensin-aldosterone systems, which can also adversely affect myocardial metabolism in heart failure. The impairment of myocardial metabolism can contribute to the progression of left ventricular remodeling and contractile dysfunction in heart failure. Although angiotensin II receptor blockers (ARBs) have been used to treat patients with DCMP, there has been no direct comparison of the efficacy of these agents. The objective of this study is to compare the effects of olmesartan and valsartan on myocardial metabolism in patients with DCMP. METHODS/DESIGN: The OVOID study (a comparison study of Olmesartan and Valsartan On myocardial metabolism In patients with Dilated cardiomyopathy) is designed as a non-blinded, open-label, parallel-group, prospective, randomized, controlled, multicenter clinical trial. A total of 40 DCMP patients aged between 20 and 85 years will be randomly allocated into the olmesartan or the valsartan group. (18)F-fluoro-2-deoxyglucose (FDG) cardiac positron emission tomography (PET) will be performed at baseline and six months after receiving the study agent. The primary endpoint is myocardial glucose consumption per square meter, measured using (18)F-FDG PET 6 months after receiving the study agent. DISCUSSION: The purpose of this trial is to compare the efficacy between olmesartan and valsartan in improving myocardial metabolism in DCMP patients. This will be the first randomized comparative study investigating the differential effects of ARBs on heart failure. TRIAL REGISTRATION: ClinicalTrials.govNCT04174456. Registered on 18 November 2019 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-021-05970-7. |
format | Online Article Text |
id | pubmed-8760768 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-87607682022-01-18 Design and rationale for a comparison study of Olmesartan and Valsartan On myocardial metabolism In patients with Dilated cardiomyopathy (OVOID) trial: study protocol for a randomized controlled trial Jo, Sua Moon, Hyeyeon Park, Kyungil Sohn, Chang-Bae Kim, Jeonghwan Kwon, Yong-Seop Kim, Su Hong Trials Study Protocol BACKGROUND: Dilated cardiomyopathy (DCMP) is characterized by ventricular chamber enlargement and systolic dysfunction which may cause heart failure. Patients with DCMP have overactivation of the renin-angiotensin-aldosterone systems, which can also adversely affect myocardial metabolism in heart failure. The impairment of myocardial metabolism can contribute to the progression of left ventricular remodeling and contractile dysfunction in heart failure. Although angiotensin II receptor blockers (ARBs) have been used to treat patients with DCMP, there has been no direct comparison of the efficacy of these agents. The objective of this study is to compare the effects of olmesartan and valsartan on myocardial metabolism in patients with DCMP. METHODS/DESIGN: The OVOID study (a comparison study of Olmesartan and Valsartan On myocardial metabolism In patients with Dilated cardiomyopathy) is designed as a non-blinded, open-label, parallel-group, prospective, randomized, controlled, multicenter clinical trial. A total of 40 DCMP patients aged between 20 and 85 years will be randomly allocated into the olmesartan or the valsartan group. (18)F-fluoro-2-deoxyglucose (FDG) cardiac positron emission tomography (PET) will be performed at baseline and six months after receiving the study agent. The primary endpoint is myocardial glucose consumption per square meter, measured using (18)F-FDG PET 6 months after receiving the study agent. DISCUSSION: The purpose of this trial is to compare the efficacy between olmesartan and valsartan in improving myocardial metabolism in DCMP patients. This will be the first randomized comparative study investigating the differential effects of ARBs on heart failure. TRIAL REGISTRATION: ClinicalTrials.govNCT04174456. Registered on 18 November 2019 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-021-05970-7. BioMed Central 2022-01-15 /pmc/articles/PMC8760768/ /pubmed/35033178 http://dx.doi.org/10.1186/s13063-021-05970-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Study Protocol Jo, Sua Moon, Hyeyeon Park, Kyungil Sohn, Chang-Bae Kim, Jeonghwan Kwon, Yong-Seop Kim, Su Hong Design and rationale for a comparison study of Olmesartan and Valsartan On myocardial metabolism In patients with Dilated cardiomyopathy (OVOID) trial: study protocol for a randomized controlled trial |
title | Design and rationale for a comparison study of Olmesartan and Valsartan On myocardial metabolism In patients with Dilated cardiomyopathy (OVOID) trial: study protocol for a randomized controlled trial |
title_full | Design and rationale for a comparison study of Olmesartan and Valsartan On myocardial metabolism In patients with Dilated cardiomyopathy (OVOID) trial: study protocol for a randomized controlled trial |
title_fullStr | Design and rationale for a comparison study of Olmesartan and Valsartan On myocardial metabolism In patients with Dilated cardiomyopathy (OVOID) trial: study protocol for a randomized controlled trial |
title_full_unstemmed | Design and rationale for a comparison study of Olmesartan and Valsartan On myocardial metabolism In patients with Dilated cardiomyopathy (OVOID) trial: study protocol for a randomized controlled trial |
title_short | Design and rationale for a comparison study of Olmesartan and Valsartan On myocardial metabolism In patients with Dilated cardiomyopathy (OVOID) trial: study protocol for a randomized controlled trial |
title_sort | design and rationale for a comparison study of olmesartan and valsartan on myocardial metabolism in patients with dilated cardiomyopathy (ovoid) trial: study protocol for a randomized controlled trial |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760768/ https://www.ncbi.nlm.nih.gov/pubmed/35033178 http://dx.doi.org/10.1186/s13063-021-05970-7 |
work_keys_str_mv | AT josua designandrationaleforacomparisonstudyofolmesartanandvalsartanonmyocardialmetabolisminpatientswithdilatedcardiomyopathyovoidtrialstudyprotocolforarandomizedcontrolledtrial AT moonhyeyeon designandrationaleforacomparisonstudyofolmesartanandvalsartanonmyocardialmetabolisminpatientswithdilatedcardiomyopathyovoidtrialstudyprotocolforarandomizedcontrolledtrial AT parkkyungil designandrationaleforacomparisonstudyofolmesartanandvalsartanonmyocardialmetabolisminpatientswithdilatedcardiomyopathyovoidtrialstudyprotocolforarandomizedcontrolledtrial AT sohnchangbae designandrationaleforacomparisonstudyofolmesartanandvalsartanonmyocardialmetabolisminpatientswithdilatedcardiomyopathyovoidtrialstudyprotocolforarandomizedcontrolledtrial AT kimjeonghwan designandrationaleforacomparisonstudyofolmesartanandvalsartanonmyocardialmetabolisminpatientswithdilatedcardiomyopathyovoidtrialstudyprotocolforarandomizedcontrolledtrial AT kwonyongseop designandrationaleforacomparisonstudyofolmesartanandvalsartanonmyocardialmetabolisminpatientswithdilatedcardiomyopathyovoidtrialstudyprotocolforarandomizedcontrolledtrial AT kimsuhong designandrationaleforacomparisonstudyofolmesartanandvalsartanonmyocardialmetabolisminpatientswithdilatedcardiomyopathyovoidtrialstudyprotocolforarandomizedcontrolledtrial |